The CIC contributes to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.
Publications prior to 2010 are credited to the Cancer Vaccine Cnsortium, the former name of the Cancer Immunotherapy Consortium
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, 4th Floor | New York, NY 10006-3111
(800) 992-2623(212) 832-9376Staff Directory
The final day of CICON18 explored two diverse areas—technology and the microbiome—that both have the potential to improve immunotherapy’s benefits for patients.
The third day of CICON18 explored cutting-edge strategies to identify and target the mutated markers that distinguish cancer cells.